Aims: Abnormal energy metabolism contributes to heart failure (HF) and the failing heart is energy starved. Here we tested whether augmented CK energy metabolism improves myocyte dysfunction in experimental HF. Methods and Results: We tested the response to the b-agonist isoproterenol (2.5 nM, ISO) in cardiomyocytes isolated from wild-type (WT) mice and mice over-expressing cardiac myofibrillar and mitochondrial CK (CK-M and CK-mito) from sham and HF (8 wk transverse aortic constriction, TAC) hearts, to dissect whether over-expressing CK-M or CK-mito might alter myocyte function at baseline or after an increase in energetic demand. At baseline, there were no differences in sarcomere fractional shortening (FS) or whole Ca 2þ transient amplitude in response to ISO among sham WT, CK-M or CK-mito myocytes. However, ISO impact on FS, Ca 2þ transient, time to 50 Ca 2þ decay, and sarcomere re-lengthening were all reduced in WT TAC hearts, consistent with prior reports. Conversely, over-expressing CK-M or CK-mito rescued ISO-induced inotropy in TAC myocytes. No sizable differences in ISO response were noticed in cells obtained from sham WT, CK-M or CK-mito hearts. To test whether over-expressing CK-M or CK-mito confers a degree of protection against acute oxidative stress, non-TAC myocytes were exposed to H 2 O 2 (50 mM for 10 min). The interval between the beginning of H 2 O 2 superfusion and the appearance of an irreversible arrhythmia was measured. WT and CK-M myocytes showed a similar response (359587s vs. 370560s, n¼5), whereas in CK-mito this interval was prolonged (580574s). Conclusions: Over-expressing CK-M and CK-mito under failing-TAC conditions improves myocyte contraction and relaxation, likely through preserved Ca 2þ handling; however, only the up-regulation of CK-mito can effectively buffer ROS, especially those of mitochondrial origin. Cardiac myosin light chain kinase (cMLCK) phosphorylates a single site in the regulatory light chain (RLC) of myosin to increase Ca 2þ sensitivity of myofilament contractions. A constellation of contractile protein phosphorylations in addition to RLC phosphorylation fine-tune actin-myosin myofibrillar force development to modulate cardiac performance. In the normal beating heart RLC is significantly phosphorylated (~45%) which may play a constitutive physiological role to enhance cardiac performance. Conventional cMLCK knockout mice have dilated hearts with severely compromised cardiac performance at 10 weeks of age and older. To determine if the dilated phenotype caused by cMLCK knockout is preceded by a loss of cardiac performance associated with decreased phosphorylation of RLC and other myofibrillar proteins, we generated an acute model for the conditional knockout of cMLCK. We optimized the minimal amount of tamoxifen necessary for cMLCK ablation and assessed cardiac performance measured as fractional shortening by echocardiography. Hearts were then harvested for analyses of protein contents and phosphorylations. Five consecutive daily i.p. injections of 0.5 mg tamoxifen per mouse were sufficient to reduce cMLCK 8052% by two weeks after the first tamoxifen injection. RLC phosphorylation was reduced to 1552% while left ventricular internal diameter at end-diastole significantly increased by 1.450.3 mm and fractional shortening decreased 4756%. There was no evidence of compensatory hypertrophy. Troponin-I and myosin binding protein-C phosphorylation at Ser23/24 and Ser282, respectively, did not significantly change. Both phosphorylations were reduced with propranolol treatment, which had no effect on RLC phosphorylation. These results suggest that constitutive RLC phosphorylation contributes to cardiac performance in the normal beating heart. 3001-Pos Board B431 Cardiac Remodeling in the Mouse Model of Marfan Syndrome Develops Independently from Aortic and Valvular Abnormalities Natalia Petrashevskaya, Hyun-Jin Tae, Shanon Marshall, Melissa Krawczyk, Mark Talan. LCS, National Institute on Aging, Baltimore, MD, USA. Marfan syndrome (MFS) is a multisystem disorder of connective tissue caused by mutations in fibrillin-1. Heart involvement in the Marfan syndrome patients includes aortic root dilatation, valvular insufficiency, and myocardial dysfunction; it remains unclear, however, whether alterations in myocardium are triggered by valvular and aortic pathology or they develop independently. We evaluated the age-dependent cardiac remodeling and left ventricular dysfunction in the mouse model of MFS known as Fbn1039Gþ/À mouse (Marfan HT mouse) using echocardiography, pressure-volume loop analyses and a number of histological and biochemical techniques. Marfan HT mice of 2-4 month demonstrated a hypertrophic cardiac remodeling accompanied by predominant decline of diastolic function and increased TGF-b canonical (p SMAD2/3) and non-canonical (pERK ½ and pMAPK38) signaling. Hypertrophic myocardium among older HT mice (6-14 months) was associated with two distinctly different phenotypes manifesting either dilated or constricted LV chamber. Dilatation of LV chamber was accompanied by biochemical evidence of greater mechanical stress, including elevated ERK1/2 phosphorylation and brain natriuretic peptide expression in comparison with constricted heart. Diastolic dysfunction in the older HT mice was combined with significant systolic impairment. The aortic valve regurgitation was registered in 20% of constricted group and 60% of dilated, while mitral insufficiency was observed in 40% of constricted group and 100% of dilated. In Marfan HT mice, extracellular matrix abnormalities were not associated with the increase of interstitial fibrosis and non-myocyte proliferation. In the mouse model of fibrillin-1 haploinsufficiency the early onset of hypertrophic cardiac remodeling and dysfunction is not consequent to functional valvular abnormalities, but it is likely to result from deficient mechanosensing and transmission of mechanical forces.
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Transgenic Over-Expression of Carbonic Anhydrase III in Cardiac Muscle Demonstrates a Mechanism to Resist Acidosis Hanzhong Feng, Jian-Ping Jin. Physiology Department, Wayne State University, Detroit, MI, USA. Carbonic anhydrase III (CAIII) is an abundant protein in skeletal muscle, liver and adipose cells. A cytosolic enzyme that catalyzes conversions between CO 2 and HCO 3 -in regulating intracellular pH, its physiological function in muscle is unclear. Mice lacking CAIII showed lower than wild type intracellular pH in skeletal muscle cells during fatigue treatment. To further understand the role of CAIII in muscle functions and stress adaptation, we developed transgenic mice overexpressing CAIII in the heart under the control of a cloned myosin heavy chain promoter for phenotype comparisons with wild type mouse hearts that are CAIII negative. Three months old transgenic mice showed normal cardiac phenotypes under non-stress conditions. Cardiac function was examined using ex vivo working heart preparations under normal and low pH conditions to investigate CAIII function in pH regulation of cardiac muscle. With equilibration of 5% CO 2 generating pH 7.4 in normal Kreb's perfusion buffer, 10% CO 2 was used to lower pH to 7.0. Functional data showed that transgenic and wild type hearts had similar pumping functions under normal pH. Perfused with low pH buffer, heart functions of both groups were decreased. In comparison with wild type controls at low pH, CAIII transgenic mouse hearts showed higher left ventricular pressure development and systolic and diastolic velocities under both baseline conditions and increased afterload stress, indicating a better tolerance to acidosis. The results suggest that CAIII may function in compensating for intracellular pH under acidotic conditions, a tractive novel approach to develop new treatment of chronic congestive heart failure.
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Myocardial Interstitial Serotonin and its Major Metabolite, 5-Hydroxyindole Acetic Acid Levels Determined by Microdialysis Technique in vivo Rat Heart Cheng-Kun Du, Dong-Yun Zhan, Tsuyoshi Akiyama, Takashi Sonobe, Tadakatsu Inagaki, Mikiyasu Shirai. National Cerebral and Cardiovascular Center Research Institute, Osaka, Japan. Aims: The aim of this study was to elucidate myocardial interstitial serotonin (5-HT) kinetics in the heart, including 5-HT reuptake and enzymatic degradation to 5-hydroxyindole acetic acid (5-HIAA) via monoamine oxidase (MAO). Main methods: Using microdialysis technique in anaesthetized rats, we simultaneously monitored myocardial interstitial levels of 5-HT and its major metabolite, 5-HIAA, in the left ventricle and examined the effects of local administration of a MAO inhibitor, pargyline, or a 5-HT uptake inhibitor, fluoxetine.
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